Mycophenolate Mofetil Arrow

Mycophenolate Mofetil, the active ingredient in Mycophenolate Mofetil Arrow, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is employed to prevent acute organ‑transplant rejection and to treat certain autoimmune diseases such as lupus nephritis.

GNH USA supplies Mycophenolate Mofetil Arrow as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil is used in the management of immune‑mediated conditions, particularly where suppression of lymphocyte proliferation is required.

- Organ transplantation (kidney, heart, liver): helps prevent acute rejection episodes. - Lupus nephritis: contributes to renal protection and disease control. - Certain other autoimmune disorders: may be added to standard regimens to reduce disease activity.

Adverse reactions can range from mild to severe and should be monitored throughout therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools. - Vomiting: occasional episodes. - Abdominal pain: cramping or discomfort. - Headache: transient mild pain. - Tremor: fine shaking of hands.

Serious or Rare Side Effects: - Leukopenia: significant reduction in white blood cells. - Anemia: decreased red blood cell count. - Severe infections: opportunistic or viral infections such as CMV. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Malignancy: increased risk of certain cancers with long‑term use. - Severe allergic reactions: rash, angioedema, or anaphylaxis.

Before initiating therapy, clinicians should assess baseline laboratory values and patient risk factors.

- Monitor blood counts: perform regular CBC to detect leukopenia or anemia. - Assess renal function: adjust dosing in patients with impaired clearance. - Avoid in pregnancy: category X, teratogenic risk mandates strict contraception. - Breastfeeding contraindicated: drug excreted in milk. - Live vaccines: avoid during treatment due to immunosuppression. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Mycophenolate Mofetil may interact with several concomitant medicines, altering efficacy or safety.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression. - Rifampin or other strong CYP3A4 inducers: markedly reduced mycophenolate exposure. - Cholestyramine or colestipol: decreased absorption when taken concurrently.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: potential for increased renal toxicity. - NSAIDs: may worsen renal impairment. - Live vaccines: heightened risk of infection; consider timing or alternative immunization.